Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

By | May 17, 2021
Researchers in the United States have conducted a study showing the efficacy of the Moderna and Pfizer-BioNTech vaccines at eliciting a robust T cell response against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).